The procurement list (see table below) of sentosa SQ HIV genotyping reagents kits and consumables from vela diagnostics, INC are required for performing the FDA-approved NGS HIV-1 drug resistance…
Ended Purchase Order Awarded Last action
- Contract number
- 75D30124P00086
- Awardee
-
Vela Diagnostics USA Inc. UEI SXXPSVGJPQM4
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $31,206
Award facts
- Opportunity
-
- Vela Diagnostics Inc. test kits Solicitation · HCWBB202400236 · Posted Aug 26, 2024
- Contract value 100% obligated
- $31,206.40 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Fairfield, NJ 07004, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Other Administrative Action | $0 | |
| Original award | $31,206 |
About this award
The Centers for Disease Control and Prevention (CDC) awarded a $31,206.40 firm fixed-price purchase order to Vela Diagnostics USA Inc. for Sentosa SQ HIV Genotyping Reagents Kits and consumables required to perform the FDA-approved Next Generation Sequencing (NGS) HIV-1 drug resistance assay. This sole-source award, issued on October 1, 2024, with an ultimate completion date of the same date, was made under FAR 13.106-1(b) authority, as Vela Diagnostics is the only manufacturer of these specialized FDA-approved test kits. The place of performance is Fairfield, New Jersey, where Vela Diagnostics maintains its primary operations. No set-aside designation was applied to this procurement.
The Sentosa SQ HIV Genotyping Assay is an automated system that performs the complete laboratory workflow from sample processing through result reporting, including viral extraction, reverse transcription polymerase chain reaction (RT-PCR), library preparation, sequencing, data analysis, and HIV drug resistance reporting. This acquisition supports the CDC's disease surveillance, prevention, and research mission, particularly in monitoring HIV drug resistance patterns critical for public health response and treatment guidance. Vela Diagnostics, a global provider of molecular diagnostic solutions specializing in infectious disease testing, has established itself as a key supplier to federal health agencies through its expertise in NGS technologies and advanced genotyping assays.
Description
The procurement list (see table below) of sentosa SQ HIV genotyping reagents kits and consumables from vela diagnostics, INC are required for performing the FDA-approved NGS HIV-1 drug resistance assay. Because IT is an FDA approved NGS assay, the SE
Quick answers
Who was awarded contract 75D30124P00086?
75D30124P00086 was awarded to Vela Diagnostics USA Inc. by CDC Pittsburgh (Centers for Disease Control and Prevention) on October 1, 2024.
How much is contract 75D30124P00086 worth?
The government has obligated $31,206 on 75D30124P00086.
Was contract 75D30124P00086 competed?
The extent of competition for 75D30124P00086 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award